Biosyngen is developing multiple T-cell immunotherapies with the aim to address a wide range of malignancies.
Our Vision is to harness the immune system for better therapeutic responses.
Our Mission is to develop most advanced immune cell therapies for aggaressive cancers
Biosyngen has world leading innovative T cell therapies, worldwide exclusive license of best-in-class technology from top-tier research institutes, and talents from Singapore, China, Germany, Australia and France;
Based on the combination of technology transfer and in-house R&D, Biosyngen is focusing on the unmet needs in cancer treatment.
Biosyngen is dedicated to eradicate tumor with immune cell therapies and benefit patients in Asia and worldwide;
Biosyngen has established world largest EBV CAR and TCR library and is conducting clinical trials in multiple centers targeting multiple indications such as nasopharyngeal caner, gastric cancer and lymphoma.